AVB-101 will now benefit from the FDA’s fast track process, which is designed to improve the efficiency of product development and accelerate the review of treatments for serious conditions.
FTD, a form of early-onset dementia, is the leading cause of dementia in people aged under 65 years and typically leads to death within seven to 13 years of symptom onset.
Genetic FTD cases account for about one-third of cases and are most frequently associated with autosomal dominant mutations in three genes, including the progranulin (GRN) gene.
